REHOVOT, Israel, July 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed public offering of its ordinary shares. All of the shares will be offered by the Company.
Jefferies LLC and Cowen and Company, LLC will act as joint book runners for the proposed offering.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from either: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor, New York, NY 10022, phone: 877-847-6340, email: Prospectus_Department@Jefferies.com, or Cowen and Company, LLC, Attn: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, phone: 631-274-2806, fax: 631-254-7140.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.
|Oded S. Lieberman, PhD MBA, CEO|
|Tel.: +972-8-946 2729|
|Cell: +1-617-517 6077|
|U.S. Investor Contact:|
|Lazar Partners Ltd.|